scholarly journals Therapeutic effects and prognostic factors of 125I brachytherapy for pelvic recurrence after early cervical cancer surgery

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Rui Wang ◽  
Jinhu Zhu ◽  
Shu Yang ◽  
Xiaoqin Chen ◽  
Cairu Gu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factors ◽  
Survival Rates ◽  
Cancer Surgery ◽  
Pelvic Recurrence ◽  
Effective Control ◽  
Control Group ◽  
Seed Implantation ◽  
Pelvic Tumour ◽  
Early Cervical Cancer

AbstractTo investigate the efficacy of 125I seed implantation in the treatment regimen of pelvic recurrence after early cervical cancer surgery and to analyse prognostic factors. To evaluate efficacy and analyse prognostic factors of 125I seed implantation for pelvic recurrence after early cervical cancer surgery. A prospective study was conducted on 62 patients who experienced pelvic recurrence after early cervical cancer surgery between August 2005 and September 2015. The 62 patients were treated and assessed in 2 groups (n = 30). All 62 patients were randomized into two groups that received two different treatment regimens: the treatment group (n = 30), which received 125I particle implantation therapy, and the control group (n = 32), which received whole-pelvic irradiation using the anteroposterior/posteroanterior field and cisplatin-based concurrent chemoradiation therapy. The efficacy/efficiency of 125I seed implantation and prognostic factors were analysed by logistic regression. Overall survival was determined by Kaplan–Meier analysis. Multivariate analysis results were obtained by the Cox proportional hazards regression model. The effective control rates at 1, 3, 6 and 12 months were 76.7%, 80.0%, 83.3%, and 86.7% in the 125I particle implantation group. The total effective control rates at 1, 3, 6 and 12 months were 65.6%, 65.5%, 62.5%, and 71.9% in the chemoradiotherapy group. Significant differences were observed between the two groups. The overall survival rates at 1, 2, 3, 4, and 5 years and the median overall were 96.7%, 93.3%, 86.7%, 71.9%, 65.6% and 4.34 years, respectively, in the 125I seed implantation group and 81.3%, 71.9%, 62.5%, 56.3%, 53.1% and 3.59 years, respectively, in the control group. There were statistically significant differences in survival rates depending on the diameter of the largest recurrent pelvic tumour (χ2 = 6.611, P = 0.010). The multivariate analysis showed that the survival rates were related to the diameter of the largest recurrent pelvic tumour (χ2 = 4.538, P = 0.033). 125I implantation is an effective, safe, and promising method for the treatment of pelvic recurrence after early cervical cancer surgery. The diameter of the recurrent pelvic tumour was identified as a significant independent prognostic factor in patients who received 125I implantation.

scholarly journals Survival impact of additional chemotherapy after adjuvant concurrent chemoradiation in patients with early cervical cancer who underwent radical hysterectomy

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Se Ik Kim ◽  
Jeong Yun Kim ◽  
Chan Woo Wee ◽  
Maria Lee ◽  
Hee Seung Kim ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Radical Hysterectomy ◽  
Figo Stage ◽  
Concurrent Chemoradiation ◽  
Survival Outcomes ◽  
Control Group ◽  
Study Group ◽  
Additional Chemotherapy ◽  
Risk Patients ◽  
Early Cervical Cancer

Abstract Background To determine whether additional chemotherapy after concurrent chemoradiation (CCRT) improves survival outcomes in patients with early cervical cancer who undergo radical hysterectomy (RH). Methods We included high- or intermediate-risk patients from two institutions, with 2009 FIGO stage IB–IIA, who underwent primary RH and pelvic lymphadenectomy between January 2007 and June 2020, and had completed adjuvant CCRT. Survival outcomes were compared between patients who received additional chemotherapy (study group) and those who did not (control group). Results A total of 198 patients were included in this analysis. The study (n = 61) and control groups (n = 137) had similar patient age, histologic cancer type, 2009 FIGO stage, and tumor size. However, minimally invasive surgery was performed less frequently in the study group than in the control group (19.7% vs. 46.0%, P < 0.001). The presence of pathologic risk factors was similar, except for lymph node metastasis, which was more frequent in the study group (72.1% vs. 46.0%; P = 0.001). In survival analyses, no differences in the disease-free survival (DFS; P = 0.539) and overall survival (OS; P = 0.121) were observed between the groups. Multivariate analyses adjusting for surgical approach and other factors revealed that additional chemotherapy was not associated with DFS (adjusted HR, 1.149; 95% CI, 0.552–2.391; P = 0.710) and OS (adjusted HR, 1.877; 95% CI, 0.621–5.673; P = 0.264). The recurrence patterns did not differ with additional chemotherapy. Consistent results were observed in a subset of high-risk patients (n = 139). Conclusions Additional chemotherapy after CCRT might not improve survival outcomes in patients with early cervical cancer who undergo RH.

Surgically-treated early cervical cancer: Prognostic factors and the significance of depth of tumor invasion

1999 ◽  
Vol 9 (3) ◽  
pp. 212-219 ◽  
Author(s):  
Hellebrekers ◽  
Zwinderman ◽  
Kenter ◽  
Peters ◽  
Snijders-Keilholz ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factors ◽  
Tumor Invasion ◽  
Early Cervical Cancer

A Prospective Study of Postoperative Lymphedema After Surgery for Cervical Cancer

2010 ◽  
Vol 20 (5) ◽  
pp. 900-904 ◽  
Author(s):  
Michael J. Halaska ◽  
Marta Novackova ◽  
Ivana Mala ◽  
Marek Pluta ◽  
Roman Chmel ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lower Limb ◽  
Bioelectrical Impedance ◽  
Impedance Analysis ◽  
Conservative Surgery ◽  
Cancer Surgery ◽  
Lower Limbs ◽  
Control Group ◽  
The Right ◽  
A Prospective Study

Objective:Lymphedema is a severe postoperative complication in oncological surgery. Multifrequency bioelectrical impedance analysis (MFBIA) is a new method for early lymphedema detection. The objective was to establish the methodology of MFBIA for lower-limb lymphedema and to detect a lymphedema in patients undergoing cervical cancer surgery.Methods:From a population of 60 patients undergoing cervical cancer surgery, 39 underwent radical hysterectomy Wertheim III (RAD group), and 21 underwent conservative surgery (laparoscopic lymphadenectomy plus simple trachelectomy/simple hysterectomy - CONS group). A control group of 29 patients (CONTR group) was used to determine the SD of impedance at zero frequency (R0). Patients were examined before surgery and at 3 and 6 months after surgery by MFBIA and by measuring the circumference of the lower limbs.Results:No differences were found between the CONS and RAD groups on age, height, weight, and histopathologic type of tumor. However, the number of dissected lymph nodes differed significantly between the groups (17.3 in the CONS group vs 25.8 in the RAD group,P= 0.0012). The SD ofR0in the CONTR group was 36.0 and 39.0 for the right and the left leg, respectively. No difference in prevalence of lymphedema based on circumference method was found (35.9% in the RAD and 47.6% in the CONS groups, not statistically significant).Conclusions:No difference in the prevalence of lymphedema was found between the CONS and RAD groups. A methodology for MFBIA for the detection of lower-limb lymphedema was described.

scholarly journals Chinese Expert Consensus on Iodine125 Seed Implantation for Recurrent Cervical Cancer in 2021

2021 ◽  
Vol 11 ◽  
Author(s):  
Ping Jiang ◽  
Lijuan Zou ◽  
Lichun Wei ◽  
Guanghui Cheng ◽  
Baosheng Sun ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Performance Status ◽  
Three Dimensional ◽  
Pelvic Recurrence ◽  
Planning System ◽  
Treatment Planning System ◽  
Recurrent Cervical Cancer ◽  
Efficient Treatment ◽  
Seed Implantation ◽  
Poor Seed

The treatment modality for recurrent cervical cancer (rCC) is limited, and the prognosis of these patients is poor. Seed implantation could be an important component of rCC management in the context of dose boost or salvage therapy after surgery or radiotherapy, which is characterized by a minimally invasive, high local dose, and rapidly does fall, sparing normal tissue. For patients with good performance status and lateral pelvic wall recurrence with an available puncture path, seed implantation was recommended, as well as for selected central pelvic recurrence and extra-pelvic recurrence. The combination of brachytherapy treatment planning system and CT guidance was needed, and three-dimensional printing templates could greatly improve the accuracy, efficiency, and quality of seed implantation to achieve a potential ablative effect and provide an efficient treatment for rCC. However, the recommendations of seed implantation were mainly based on retrospective articles and lack high-quality evidence, and multicenter prospective randomized studies are needed. In this consensus on iodine125 seed implantation for rCC, indication selection, technical process and requirements, dosimetry criteria, radiation protection, combined systemic therapy, and outcomes of seed implantation for rCC are discussed.

The Prognostic Factors for Patients with Early Cervical Cancer Treated by Radical Hysterectomy and Postoperative Radiotherapy

1999 ◽  
Vol 75 (3) ◽  
pp. 328-333 ◽  
Author(s):  
Chien-Sheng Tsai ◽  
Chyong-Huey Lai ◽  
Chun-Chieh Wang ◽  
Joseph T. Chang ◽  
Ting-Chang Chang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factors ◽  
Radical Hysterectomy ◽  
Postoperative Radiotherapy ◽  
Early Cervical Cancer

scholarly journals Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

2015 ◽  
Vol 33 (19) ◽  
pp. 2136-2142 ◽  
Author(s):  
Peter G. Rose ◽  
James Java ◽  
Charles W. Whitney ◽  
Frederick B. Stehman ◽  
Rachelle Lanciano ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factors ◽  
Gynecologic Oncology ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Pelvic Recurrence ◽  
Gynecologic Oncology Group ◽  
Advanced Cervical Cancer ◽  
Free Survival ◽  
Locally Advanced Cervical Cancer

Purpose To evaluate the prognostic factors in locally advanced cervical cancer limited to the pelvis and develop nomograms for 2-year progression-free survival (PFS), 5-year overall survival (OS), and pelvic recurrence. Patients and Methods We retrospectively reviewed 2,042 patients with locally advanced cervical carcinoma enrolled onto Gynecologic Oncology Group clinical trials of concurrent cisplatin-based chemotherapy and radiotherapy. Nomograms for 2-year PFS, five-year OS, and pelvic recurrence were created as visualizations of Cox proportional hazards regression models. The models were validated by bootstrap-corrected, relatively unbiased estimates of discrimination and calibration. Results Multivariable analysis identified prognostic factors including histology, race/ethnicity, performance status, tumor size, International Federation of Gynecology and Obstetrics stage, tumor grade, pelvic node status, and treatment with concurrent cisplatin-based chemotherapy. PFS, OS, and pelvic recurrence nomograms had bootstrap-corrected concordance indices of 0.62, 0.64, and 0.73, respectively, and were well calibrated. Conclusion Prognostic factors were used to develop nomograms for 2-year PFS, 5-year OS, and pelvic recurrence for locally advanced cervical cancer clinically limited to the pelvis treated with concurrent cisplatin-based chemotherapy and radiotherapy. These nomograms can be used to better estimate individual and collective outcomes.

Therapeutic efficacy of epidermal growth factor receptor monoclonal antibody combined with concurrent chemoradiotherapy in treatment of locally advanced cervical cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17012-e17012
Author(s):  
Wenli Chen ◽  
Tao Li ◽  
Wei Zhang ◽  
Jialin Yang ◽  
Jian Wang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Control Group ◽  
Study Group ◽  
Advanced Cervical Cancer ◽  
Free Survival ◽  
Locally Advanced Cervical Cancer

e17012 Background: There are few studies about epidermal growth factor receptor monoclonal antibody nimotuzumab for the treatment of locally advanced cervical cancer. We aimed to assess the therapeutic efficacy and analyse prognostic factors of chemoradiotherapy combined with nimotuzumab in cervical cancer (stage IIB-IVA) . Methods: We retrospectively analyzed 23 patients with locally advanced cervical cancer(stage IIB-IVA) ,who received concurrent chemoradiotherapy combined with nimotuzumab from 2012 to 2014 (the study group) ,and 30 patients with the similar baseline characteristics who received concurrent chemoradiotherapy alone (the control group). The overall response rates, 5-year overall survival rates, progression-free survival and acute adverse events of the two groups were compared .Multivariate prognostic analysis was performed by a Cox proportional hazards model. Results: The median follow-up time were 46 months (IQR 16-60) in the study group and 42 months (2-60) in the control group.The overall response rates were 87% and 73.3% (P = 0.384) . The 5-year overall survival rates were 63.6% and 36.1% (hazard ratio 2.208,95% CI 0.878-5.557,P = 0.092) .The median progression-free survival in the study group was not achieved (95%CI 9-55) versus 27 months (1-60) in the control group (hazard ratio 2.635, 95% CI 1.030-6.737, P= 0.043).Multivariate prognostic analysis indicated that stage and whether to be combined with nimotuzumab were the influential factors for progression-free survival time.Adverse events were similar between groups.The most common grade 3 or 4 adverse events during treatment in the study group versus the control group were leucopenia(9 [39%] vs 11 [36%]),thrombocytopenia (3 [13%] vs 6 [20%]),anaemia (4 [17%] vs 4 [13%]). Conclusions: Concurrent chemoradiotherapy combined with nimotuzumab in the treatment can improve the progression-free survival time of advanced cervical cancer, while not increasing the incidence of adverse reactions.However, because of the small size of sample in this research, these findings suggest that it is necessary to perform a prospective study with expanded sample size.

scholarly journals An Analysis of Long-Term Outcomes in Patients with Locally Advanced Cervical Cancer Treated by Chemoradiation with Reference to the Additional Performance of Hysterectomy Due to Emergency Vaginal Bleeding or Hemorrhage.

2020 ◽  
Author(s):  
Agnieszka Lewandowska ◽  
Lukasz Wicherek ◽  
Krzysztof Koper ◽  
Sebastian Szubert ◽  
Joanna Terlikiewicz ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Survival Data ◽  
Vaginal Bleeding ◽  
Locally Advanced ◽  
Survival Rates ◽  
Control Group ◽  
Severe Bleeding ◽  
Advanced Cervical Cancer ◽  
Locally Advanced Cervical Cancer ◽  
Initial Surgery

Abstract AimStandard treatment for locally advanced cervical cancer patients (LACC) consists of chemoradiation followed by vaginal brachytherapy. However, many patients with LACC surgery undergo surgical treatment with hysterectomy during comprehensive cancer treatment. The aim of the present study has been to analyze the survival data of those who underwent hysterectomy due to vaginal bleeding or hemorrhage prior to definitive chemoradiation. Materials and methodsThe study group included 35 patients with stage IIB (according to the FIGO classification) cervical cancer who received chemoradiation following salvage hysterectomy performed because of severe bleeding. The control group consisted of 44patients with stage IIB cervical cancer treated with primary chemoradiation without completion hysterectomy. ResultsThe median period for patient follow-up was 100 months. We did not observe inferior survival rates among the patients treated with salvage hysterectomy prior to chemoradiation compared to those treated with chemoradiation alone (P=0.77). The 5-year survival rate for patients treated with initial surgery was 62% compared to 61% for those treated with primary chemoradiation. Six (17%) patients from the group treated with hysterectomy experienced severe adverse events. ConclusionWhen hysterectomy due to vaginal bleeding or hemorrhage in patients with locally advanced cervical cancer is performed prior to chemoradiation, it may have curative significance and provide some overall survival benefit.

scholarly journals Pengaruh pengetahuan perempuan pasangan usia subur terhadap upaya melakukan deteksi dini kanker serviks

2020 ◽  
Vol 9 (1) ◽  
pp. 61
Author(s):  
Nurul Soimah
Keyword(s):  
High School ◽  
Cervical Cancer ◽  
Junior High School ◽  
Univariate Analysis ◽  
Reproductive Age ◽  
Wilcoxon Test ◽  
Control Group ◽  
Childbearing Age ◽  
Early Cervical Cancer ◽  
The One

Cervical cancer is a malignant disease that attacks the female uterine organ. Data of Health Office D.I. Yogyakarta 2014 show that most cancer sufferers come from age 25 -64 years, adolescents 15-24 years, The study was conducted in order to know the effect of knowledge on women of childbearing age efforts to conduct early detection of cervical cancer, the explanatory research design of The One Group Pretest-posttest Design experimental study without a control group. The study population in the Aisyiyah recitation group 'Aisyiyah Hamlet Ganggom, Bangunkerto, Turi, Sleman, the total population of 31 people, sampling techniques in total sampling, obtained a sample of 26 respondents who have met the inclusion criteria of women of reproductive age 20-35, educated at least graduated from junior high school, data collection using the adoption questionnaire from Setianingsih and Soimah, (2017), univariate analysis calculated percentage, bivariate using Wilcoxon test. The highest age characteristics of 20-30 years old amounted to 14 (53.8%) respondents, Educational factors most of the last high school education totaled 19 people (73%), the highest level of knowledge before counseling was 14 people (53.8%). after counseling, knowledgeable EFAs were increasing to 21 people (80.8%). Wilcoxon test knowledge of pre and post counseling with prevention efforts obtained with a value of p = 1.34> α (0.05) can be concluded that there is no effect of counseling on knowledge of EFA to changes in the behavior of prevention of early cervical cancer.

Sign in / Sign up

Export Citation Format

Share Document